TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00298363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir DF; TDF)
Description: 300-mg tablet QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
Description: FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Description: 0.5-mg or 1-mg tablet QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF placebo
Description: Placebo to match TDF QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF placebo
Description: Placebo to match TDF QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF placebo
Description: Placebo to match FTC/TDF QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF placebo
Description: Placebo to match FTC/TDF QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV placebo
Description: Placebo to match ETV QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV placebo
Description: Placebo to match ETV QD
Study: NCT04191343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab injection combined with GEMOX
Description: Toripalimab Injection (240mg, intravenous drip, d1, q3w);Combined with gemcitabine (1000mg/m2, intravenous drip, d1, d8, q3w) and oxaliplatin (100mg/m2, intravenous drip, d1, q3w)
Study: NCT05742113

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo Radical-7
Description: perfusion index measuring device
Study: NCT03323970

Intervention type: OTHER
Intervention: semi-structured interviews
Description: individual semi-structured interviews
Study: NCT03105856

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CERVARIX
Description: - HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 month). This group will receive the HPV16/18 vaccine containing HPV16 and HPV18 L1 virus-like-particles (20 μg of each) adjuvanted with 50 μg 3-O-desacyl-4'-monophosphoryl lipid A and 0.5 mg aluminum hydroxide (GlaxoSmithKline Biologicals, Rixensart, Belgium). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CERVARIX
Description: - HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 month). This group will receive the HPV16/18 vaccine containing HPV16 and HPV18 L1 virus-like-particles (20 μg of each) adjuvanted with 50 μg 3-O-desacyl-4'-monophosphoryl lipid A and 0.5 mg aluminum hydroxide (GlaxoSmithKline Biologicals, Rixensart, Belgium). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL
Description: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) recombinant vaccine according to a two dose schedule (0-12 month). This group will receive amorphous aluminum hydroxyphosphate sulfate adjuvanted quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine (Merck Sharp \& Dohme Corp. Whitehouse Station, NJ, USA). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GARDASIL
Description: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) recombinant vaccine according to a two dose schedule (0-12 month). This group will receive amorphous aluminum hydroxyphosphate sulfate adjuvanted quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine (Merck Sharp \& Dohme Corp. Whitehouse Station, NJ, USA). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
Study: NCT03955900

Intervention type: OTHER
Intervention: No intervention
Description: Both retrospective and prospective data will be collected. The retrospective data will be collected through medical chart review.
Study: NCT00135356

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)
Description: Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
Description: Protease inhibitor \[PI\] combination + 2 NRTIs
Study: NCT00153816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: 3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: 3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: 3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: 3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 1000 IU/daily; two tablets per day; 500 IU per tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 1000 IU/daily; two tablets per day; 500 IU per tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 1000 IU/daily; two tablets per day; 500 IU per tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo; two tablets per day
Study: NCT02222116

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGuard Prime

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control BMS DES
Study: NCT04823806

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Spermidine (spermidineLIFE ®) OR Placebo
Description: 21 day of 6mg spermidine OR Placebo supplementation per day
Study: NCT03945643

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50mg administration in gel-encapsulated microcrystalline cellulose one time, one hour prior to measurements.
Study: NCT02938897

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Registered Dietitian Nutritionist (RDN) Support
Description: RDN provided individualized medical nutrition therapy via videoconference at weeks 1, 5, and 9 and telephonic nutrition coaching support at weeks 2-4, 6-8, and 10-12.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet-related educational materials
Description: Individualized caloric recommendations (500-750 kcal reduction) were made and food-based educational materials emphasizing general healthful eating patterns and increased intakes of nutrient-rich foods were provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet-related educational materials
Description: Individualized caloric recommendations (500-750 kcal reduction) were made and food-based educational materials emphasizing general healthful eating patterns and increased intakes of nutrient-rich foods were provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-monitoring tools
Description: Self-monitoring tools including: weekly weight log, fruit and vegetable tracker, and a SMART (specific, measurable, achievable, relevant, and time bound) goal planner were provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring tools
Description: Self-monitoring tools including: weekly weight log, fruit and vegetable tracker, and a SMART (specific, measurable, achievable, relevant, and time bound) goal planner were provided.
Study: NCT05906797

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: Subgingival biofilm ultrasonic debridement
Study: NCT01130649

Intervention type: DEVICE
Intervention: HealthBuddy
Description: Noninvasive device for remotely reporting health information. The device does nothing to change the health of the patient, but transmits health data that is entered by the patient directly to the physician's office. Patients will enter data on seizure frequency, medication compliance, and side effects.
Study: NCT00952848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Pain Rating Score

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Neuropathy Scale instrument
Description: ECOG Common Toxicity Criteria for Sensory Neuropathy scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life instrument
Description: Uniscale 0-100 scale global quality of life

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MC5-A Scrambler device
Description: Electrical stimulation for 60 minutes
Study: NCT00830609

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa 2 A
Description: Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb\>12 g/dL if required over 20 additional weeks (Arm B2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2 A
Description: Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb\>12 g/dL if required over 20 additional weeks (Arm B2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2 A
Description: Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb\>12 g/dL if required over 20 additional weeks (Arm B2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2 A, ribavirin + Epo Beta
Description: Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb\>12g/dl over 4 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2 A, ribavirin + Epo Beta
Description: Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb\>12g/dl over 4 or 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: RBV 1600 mg/day 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: ribavirin 800 mg/day for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa 2
Description: Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks
Study: NCT00755417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended-Release (G-ER) 1200 mg
Description: G-ER 1200 mg daily dosage given as two 600-mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin Extended-Release (G-ER) 1800 mg
Description: G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
Study: NCT02676843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-1451
Description: A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.
Study: NCT04056793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized birthing position
Description: The parturients will be asked to adopt a supine position with a hyperflexion of the thighs and a flat back, and to maintain the position for a duration of twenty minutes.
Study: NCT04823806

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spermidine (spermidineLIFE ®) OR Placebo
Description: 21 day of 6mg spermidine OR Placebo supplementation per day
Study: NCT04321941

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lumentin
Description: Contrast agent used in combination with CTE

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Movprep
Description: Contrast agent used in combination with MRE
Study: NCT01628692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 30 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 30 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 30 mg, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablets, oral, 30 mg, once daily
Study: NCT04536298

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: Vitamin D softgel capsules; each capsule contains 3200 IU of vitamin D3. Three capsules per day (9600 IU/day) will be taken on days 1 and 2, and one capsule per day (3200 IU/day) will be taken on days 3 through 28

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo softgel capsules. Three capsules per day will be taken on days 1 and 2, and one capsule per day will be taken on days 3 through 28
Study: NCT01533688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely (polyethylene glycol electrolyte lavage solution) and placebo
Description: 4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo
Description: split dose (2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters Golytely + placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl
Description: split dose ( 2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters of Golytely + bisacodyl 10 mg
Study: NCT01741350

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-friendly Health Recovery Program
Description: Four weekly HIV risk-reduction groups and routine clinical services (i.e., daily methadone and case management).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-and-Attention-Matched Control Condition
Description: Four weekly support groups and routine clinical services (i.e., daily methadone and case management).
Study: NCT04010084

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive irradiation with a DMC-branded laser EC device, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The irradiation will be applied transcutaneously in the sublingual region (3 points on the left side and 3 points on the right side), irradiated for 30 seconds and the total treatment time will be 3 minutes. The group will receive placebo (with switched-off) irradiation of the DMC-brand laser therapy EC model, with combined wavelength (660 and 780 nm), 1J of energy per point and output power of 35 mW. A disposable plastic material covering the application pen will be used for hygiene reasons.~The treatment will be performed twice weekly for a total of 4 consecutive weeks of treatment, and after completion, the patients will be reassessed of all the complementary tests that have been requested.
Study: NCT02377128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral salpingectomy
Description: Surgical bilateral removal of fallopian tubes (not involving ovaries)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tubal ligation
Description: Bilateral ligation of fallopian tubes (not involving ovaries)
Study: NCT01830907

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: carbohydrates

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamins

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamins
Study: NCT04421157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Schroth Exercises
Description: The Schroth approach consists of 3D scoliosis-specific exercises based on kinesthetic and sensorimotor principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. The treatment program consists of scoliotic posture correction and a breathing pattern with the help of proprioceptive and exteroceptive stimulations and mirror control. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. Schroth group received Schroth exercises in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stabilization Exercises
Description: Each exercise session consisted of a warm-up exercise, core stabilization exercise, and a cool-down exercise. The core stabilization exercise was designed with consideration of local, global muscle stability training, global muscle mobility training,and strengthening training of these core structures was carried out progressively advancing more difficult. Traditional exercises program included strengthening back, abdominal, pelvis and shoulder girdle muscles and also muscles in the convex side of the curve, stretching exercises especially for the concave side of the curve, postural training, flexibility exercises for the spine, and breathing exercises. The Stabilization group received Core stabilization in addition to traditional rehabilitation for 10 weeks. Patients received 30 sessions for 90 minutes at the clinic for ten-week treatment period.
Study: NCT04578509

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasopharyngeal swab
Description: Research of SARS-CoV-2 infection in nasopharyngeal swab by RT-PCR and by antigenic test

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sample
Description: Research of SARS-CoV-2 infection in saliva samples by RT-PCR and by new detection approach

Intervention type: DIAGNOSTIC_TEST
Intervention: Saliva sample
Description: Research of SARS-CoV-2 infection in saliva samples by RT-PCR and by new detection approach

Intervention type: DIAGNOSTIC_TEST
Intervention: axillary sweat sample
Description: Research of volatile olfactory compounds of SARS-CoV-2 infection by canine detection on axillary sweat.

Intervention type: OTHER
Intervention: Data collection
Description: Demographics, symptoms, medical history, acceptability of specimen, consumption in precedents hours are collected

Intervention type: OTHER
Intervention: Data collection
Description: Demographics, symptoms, medical history, acceptability of specimen, consumption in precedents hours are collected
Study: NCT03937674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HeartSteps: A just-in-time intervention for increasing physical activity among sedentary adults.
Description: HeartSteps is a smartphone based mHealth intervention that contains the following intervention components: (1) contextually-tailored suggestions for activity; (2) motivational messages aimed at keeping individuals motivated to be active; (3) planning of the next week's activity; and (4) adaptive weekly activity goals. Activity suggestions provide individuals with suggestions for how they can be active, and are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. Motivational messages are delivered to individuals via a push notification. Activity planning asks users to create a plan of how they will be active in the coming week. Participants are prompted to plan once a week. Each week, as part of the weekly planning, HeartSteps suggests an activity goal for the coming week based on their activity levels the previous week. Participants can edit the suggested goal, and the system-suggested goals top out at 150 minutes of activity per week.
Study: NCT00662987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 7 days of amoxicillin
Description: Received 7 days of amoxicillin (dosed 40mg/kg divided bid up to maximum daily dose of 800 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3 days of amoxcillin followed by 4 days of placebo
Description: 3 days of amoxicillin (40 mg/kg divided bid up to maximum daily dose of 800 mg) followed by placebo
Study: NCT01437371

Intervention type: DRUG
Group type: OTHER
Intervention: - Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.
Description: The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months

Intervention type: DRUG
Group type: OTHER
Intervention: - Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.
Description: The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months